Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest Methylphenidate Stories

2009-05-27 22:07:42

Attention-deficit hyperactivity disorder is a modern construct that before 1957 was not considered a disorder or worth treating, a Canadian researcher said. Matthew Smith of Edmonton, finishing his doctorate at the Centre for Medical History at the University of Exeter in England, says ADHD is currently the most commonly diagnosed childhood psychiatric disorder and millions of children are prescribed drugs such as Ritalin. Smith says many today assert that ADHD is a universal phenomenon and...

fb7c93c97ae614d785cc221ab17a15931
2009-04-27 15:28:49

A new long term study has found that children taking medication for attention deficit disorder received higher scores on tests than those who did not take ADHD medication. The national study included 600 children with attention deficit hyperactivity disorder, or ADHD, and observed them from kindergarten through fifth grade. Standardized math and reading exams taken by the students during that span of time were reviewed. Measured up against those who did take ADHD medication, normal scores...

2009-04-23 09:49:00

Study shows Clonicel(R) and stimulants combined provide greater improvement in symptoms than stimulants alone DURHAM, N.C., April 23 /PRNewswire/ -- Addrenex Pharmaceuticals, Inc. today announced positive results from a second phase 3 trial of Clonicel demonstrating that the combination of Clonicel with stimulant medications provided statistically significant improvements in attention deficit hyperactivity disorder (ADHD) symptoms compared to stimulant use alone. Clonicel is the company's...

2009-04-22 07:00:00

TITUSVILLE, N.J., April 22 /PRNewswire/ -- Although Attention Deficit Hyperactivity Disorder (ADHD) is a condition commonly thought of as only affecting children, for nearly 9 million adults in the United States, ADHD is very much a reality. According to the National Institutes of Mental Health, adults with ADHD often struggle with getting organized, sticking to a job, remembering or keeping appointments and being productive. To view the Multimedia News Release, go to:...

2009-03-31 17:07:00

TITUSVILLE, N.J., March 31 /PRNewswire/ -- The U.S. District Court for the District of Delaware has rendered a decision in the patent litigation between Alza Corporation, McNeil-PPC, Inc. and Andrx Pharmaceuticals LLC. McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., which markets CONCERTA(R) (methylphenidate HCI) Extended-Release Tablets CII, said the court held that the patent in suit is not valid or infringed by the filing of Andrx's Abbreviated New Drug...

2009-03-20 07:00:00

PHILADELPHIA, March 20 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced today a voluntary market withdrawal/recall of thirty-nine (39) lots of the ADHD patch DAYTRANA (the lots of DAYTRANA patches affected by this action are listed below). Shire is taking this action because some DAYTRANA patches no longer meet their release liner removal specification, and as a result, patients and caregivers could have difficulties...

d4a1343537906ea4963cc8b69e4a33491
2009-03-18 06:55:00

A small government study suggests that the narcolepsy drug modafinil "” a so-called "smart drug" increasingly being used to enhance cognitive abilities "” may be more addictive than doctors thought, the Associated Press reported. A study involving 10 healthy men found that the prescription drug Provigil (generic name: Modafinil) caused changes in the brain's pleasure center, very much like potentially habit-forming classic stimulants. College students often use Modafinil as an...

2009-03-16 07:38:00

DUBLIN, March 16 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has decided to withdraw the European Marketing Authorization Application (MAA) for DAYTRANA(TM) (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). A request from European regulators to conduct an additional clinical study on DAYTRANA in a European patient population combined with the...

aa23779aeb2914925a4b3a045ec25d111
2009-02-23 15:03:56

Cocaine use can have toxic effects on brain cells (neurons) that produce dopamine, say experts at Baylor College of Medicine in Houston in a report that appears today in the journal Psychiatry Research.  Using brain tissue acquired after the subjects died, researchers microscopically compared the number of dopamine cells in the brains of 10 cocaine users to those in the brains of nine people matched for age who did not use the drug. They found significantly fewer dopamine cells, 16...

2009-02-20 01:00:00

PHILADELPHIA and DUBLIN, February 20 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has signed an agreement with UCB to acquire the worldwide rights to EQUASYM(R) IR and XL (methylphenidate hydrochloride) (excluding the USA, Canada and Barbados) used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). EQUASYM XL is approved and marketed in 10 countries (outside the USA, Canada, and...